BeiGene lines up a next-gen CT­LA-4 to com­ple­ment its PD-1 pil­lar in new deal worth up to $270M

BeiGene is jump­ing on the band­wag­on for PD-(L)1/CT­LA-4 com­bos — with a twist.

Through a de­vel­op­ment and com­mer­cial­iza­tion pact with San Diego-based BioAt­la, BeiGene is pair­ing its PD-1 drug tislelizum­ab with BA3071, a CT­LA-4 block­ing “con­di­tion­al­ly ac­tive bi­o­log­ic” that gets turned on or off based on whether it’s in­side the tu­mor mi­croen­vi­ron­ment.

San Diego-based BioAt­la is re­spon­si­ble for ear­ly clin­i­cal work, while BeiGene will lead the joint ef­forts there­after to de­vel­op the com­bo and deal with reg­u­la­tors around the world. The Chi­nese biotech, which is com­mit­ting $20 mil­lion up­front and $249 mil­lion in biobucks as well as a cost-shar­ing scheme, is al­so pick­ing up all costs in Asia (ex­cept Japan), Aus­tralia and New Zealand from here on out. It has a full li­cense to com­mer­cial­iza­tion rights.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER